Cyclic nucleotide signaling in polycystic kidney disease

Kidney International

Volumn 77, Issue 2, 2010, Pages 129-140

  Wang, Xiaofang ^a   Ward, Christopher J ^a   Harris, Peter C ^a   Torres, Vicente E ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

Cyclic AMP; Cyclic GMP; Polycystic kidney disease

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT MODULATOR; CYCLIC GMP; CYCLIC NUCLEOTIDE; MESSENGER RNA; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV;

ANIMAL TISSUE; ARTICLE; CATABOLISM; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; KIDNEY POLYCYSTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASES; ANIMALS; BLOTTING, WESTERN; CELL LINE; COLLAGEN; CYCLIC AMP RESPONSE ELEMENT MODULATOR; CYCLIC GMP; ISOENZYMES; MICE; POLYCYSTIC KIDNEY DISEASES; POLYMERASE CHAIN REACTION; RATS; RECEPTORS, VASOPRESSIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 73349107436     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.438     Document Type: Article

References (76)

1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287-1301.
2. Torres VE, Grantham JJ. Cystic Diseases of the Kidney In8th edn, Chapter 41. Brenner & Rector: Bermedica, 2007.
3. Somlo S, Torres VE, Caplan MJ. Autosomal dominant polycystic kidney disease and inherited cystic disease. In: Alpern RJ, Hebert SC (eds). The Kidney. In 4th edn, 2007 pp, 2283-2313 (Chapter 81).
4. Guay-Woodford LM, Desmond RA. Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics 2003; 111: 1072-1080.
5. Adeva M, El-Youssef M, Rossetti S et al. Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) 2006; 85: 1-21.
6. Gunay-Aygun M, Avner ED, Bacallao RL et al. Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a First National Institutes of Health/Office of Rare Diseases conference. J Pediatr 2006; 149: 159-164.
7. Grantham JJ. Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach. Kidney Int 2003; 64: 1157-1162.
8. Yamaguchi T, Nagao S, Wallace DP et al. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 2003; 63: 1983-1994.
9. Hanaoka K, Guggino W. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 2000; 11: 1179-1187.
10. Yamaguchi T, Wallace DP, Magenheimer BS et al. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 2004; 279: 40419-40430.
11. Yamaguchi T, Hempson SJ, Reif GA et al. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 2006; 17: 178-187.
12. Yamaguchi T, Nagao S, Kasahara M et al. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 1997; 30: 703-709. (Pubitemid 27465366)
13. Gattone VH, Wang X, Harris PC et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nature Med 2003; 9: 1323-1326.
14. Torres VE, Wang X, Qian Q et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nature Med 2004; 10: 363-364. (Pubitemid 38508512)
15. i reduction increases cellular proliferation and apoptosis in vascular smooth muscle cells: relevance to the ADPKD phenotype. Circ Res 2005; 96: 873-880.
16. Smith LA, Bukanov NO, Husson H et al. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol 2006; 17: 2821-2831.
17. Banizs B, Pike MM, Millican CL et al. Dysfunctional cilia lead to altered ependyma and choroid plexus function, and result in the formation of hydrocephalus. Development 2005; 132: 5329-5339.
18. Masyuk TV, Masyuk AI, Torres VE et al. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 30,50-cyclic monophosphate. Gastroenterology 2007; 132: 1104-1116.
19. Starremans PG, Li X, Finnerty PE et al. A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 50 end of Pkd1. Kidney Int 2008; 73: 1394-1405.
20. WS25/~. J Am Soc Nephrol 2005; 16: 361A.
21. Wang X, Wu Y, Ward CJ et al. Vasopressin directly regulates cyst growth in the PCK rat. J Am Soc Nephrol 2008; 19: 102-108.
22. Torres VE, Harris PC. Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases. Nature Clin Prac Nephro 2006; 2: 40-54.
23. Tradtrantip L, Yangthara B, Padmawar P et al. Thiophenecarboxylate suppressor of cyclic nucleotides discovered in a small-molecule screen blocks toxin-induced intestinal fluid secretion. Mol Pharmacol 2009; 75: 134-142.
24. Okada S, Misaka T, Tanaka Y et al. Aquaporin-11 knockout mice and polycystic kidney disease animals share a common mechanism of cyst formation. FASEB J 2008; 22: 3672-3684.
25. Yu J, Wolda SL, Frazier AL et al. Identification and characterisation of a human calmodulin-stimulated phosphodiesterase PDE1B1. Cell Signal 1997; 9: 519-529.
26. Polli JW, Kincaid RL. Molecular cloning of DNA encoding a calmodulin-dependent phosphodiesterase enriched in striatum. Proc Natl Acad Sci USA 1992; 89: 11079-11083.
27. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006; 58: 488-520.
28. Boletta A, Qian F, Onuchic LF et al. Polycystin-1, the gene product of PKD1, induces resistance to apoptosis and spontaneous tubulogenesis in MDCK cells. Mol Cell 2000; 6: 1267-1273.
29. Ding B, Abe J, Wei H et al. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 2005; 111: 2469-2476.
30. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006; 109: 366-398.
31. Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res 2007; 100: 309-327.
32. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007; 76: 481-511.
33. Dousa TP. Cyclic-30,50-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int 1999; 55: 29-62.
34. Yamaki M, McIntyre S, Rassier ME et al. Cyclic 30,50-nucleotide diesterases in dynamics of cAMP and cGMP in rat collecting duct cells. Am J Physiol 1992; 262: F957-F964.
35. Torres VE, Northrup TE, Edwards RM et al. Modulation of cyclic nucleotides in isolated rat glomeruli: role of histamine, carbamylcholine, parathyroid hormone, and angiotensin-II. J Clin Invest 1978; 62: 1334-1343.
36. Kusano E, Yoshida I, Takeda S et al. Nephron distribution of total low Km cyclic AMP phosphodiesterase in mouse, rat and rabbit kidney. Tohoku J Exp Med 2001; 193: 207-220.
37. 2+-calmodulin-dependent phosphodiesterase (PDE1): current perspectives. Cell Signal 2005; 17: 789-797.
38. Kakkar R, Raju RV, Sharma RK. Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1). Cell Mol Life Sci 1999; 55: 1164-1186.
39. Calvo-Garcia MA, Campbell KM, O'Hara SM et al. Acquired renal cysts after pediatric liver transplantation: association with cyclosporine and renal dysfunction. Pediatr Transplant 2008; 12: 666-671.
40. Franchi-Abella S, Mourier O, Pariente D et al. Acquired renal cystic disease after liver transplantation in children. Transplant Proc 2007; 39: 2601-2602.
41. Lien YH, Hunt KR, Siskind MS et al. Association of cyclosporin A with acquired cystic kidney disease of the native kidneys in renal transplant recipients. Kidney Int 1993; 44: 613-616.
42. Liu H, Maurice DH. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol 1998; 125: 1501-1510.
43. Houslay MD, Baillie GS, Maurice DH. cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ Res 2007; 100: 950-966.
44. Baillie GS, Scott JD, Houslay MD. Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Lett 2005; 579: 3264-3270.
45. McSorley T, Stefan E, Henn V et al. Spatial organisation of AKAP18 and PDE4 isoforms in renal collecting duct principal cells. Eur J Cell Biol 2006; 85: 673-678.
46. Stefan E, Wiesner B, Baillie GS et al. Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells. J Am Soc Nephrol 2007; 18: 199-212.
47. Le Jeune IR, Shepherd M, Van Heeke G et al. Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter. J Biol Chem 2002; 277: 35980-35989.
48. Rena G, Begg F, Ross A et al. Molecular cloning, genomic positioning, promoter identification, and characterization of the novel cyclic amp-specific phosphodiesterase PDE4A10. Mol Pharmacol 2001; 59: 996-1011.
49. 0-monophosphate (cAMP)-specific phosphodiesterase gene that confers hormone and cAMP inducibility. Mol Endocrinol 1997; 11: 839-850.
50. Cheng J, Thompson MA, Walker HJ et al. Differential regulation of mesangial cell mitogenesis by cAMP phosphodiesterase isozymes 3 and 4. Am J Physiol Renal Physiol 2004; 287: F940-F953.
51. Chini CC, Grande JP, Chini EN et al. Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4. Regulation of superoxidation and mitogenesis. J Biol Chem 1997; 272: 9854-9859.
52. Osinski MT, Schror K. Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: role of protein kinase A in vascular smooth muscle cell mitogenesis. Biochem Pharmacol 2000; 60: 381-387.
53. Matousovic K, Tsuboi Y, Walker H et al. Inhibitors of cyclic nucleotide phosphodiesterase isozymes block renal tubular cell proliferation induced by folic acid. J Lab Clin Med 1997; 130: 487-495.
54. Cheng J, Thompson MA, Walker HJ et al. Lixazinone stimulates mitogenesis of Madin-Darby canine kidney cells. Exp Biol Med (Maywood) 2006; 231: 288-295.
55. Banales JM, Masyuk TV, Gradilone SA et al. The cAMP effectors Epac and protein kinase A (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology 2009; 49: 160-174.
56. Bossis I, Stratakis CA. Minireview: PRKAR1A: normal and abnormal functions. Endocrinology 2004; 145: 5452-5458.
57. Griffioen G, Thevelein JM. Molecular mechanisms controlling the localisation of protein kinase A. Curr Genet 2002; 41: 199-207.
58. Skalhegg BS, Tasken K. Specificity in the cAMP/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA. Front Biosci 2000; 5: D678-D693.
59. Tasken K, Aandahl EM. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 2004; 84: 137-167.
60. Li X, Burrow CR, Polgar K et al. Protein kinase X (PRKX) can rescue the effects of polycystic kidney disease-1 gene (PKD1) deficiency. Biochim Biophys Acta 2008; 1782: 1-9.
61. Li X, Li HP, Amsler K et al. PRKX, a phylogenetically and functionally distinct cAMP-dependent protein kinase, activates renal epithelial cell migration and morphogenesis. Proc Natl Acad Sci USA 2002; 99: 9260-9265.
62. Zimmermann B, Chiorini JA, Ma Y et al. PrKX is a novel catalytic subunit of the cAMP-dependent protein kinase regulated by the regulatory subunit type I. J Biol Chem 1999; 274: 5370-5378.
63. Blaschke RJ, Monaghan AP, Bock D et al. A novel murine PKA-related protein kinase involved in neuronal differentiation. Genomics 2000; 64: 187-194.
64. Burton KA, Treash-Osio B, Muller CH et al. Deletion of type IIalpha regulatory subunit delocalizes protein kinase A in mouse sperm without affecting motility or fertilization. J Biol Chem 1999; 274: 24131-24136.
65. Malmberg AB, Brandon EP, Idzerda RL et al. Diminished inflammation and nociceptive pain with preservation of neuropathic pain in mice with a targeted mutation of the type I regulatory subunit of cAMP-dependent protein kinase. J Neurosci 1997; 17: 7462-7470.
66. Cho-Chung YS, Nesterova MV. Tumor reversion: protein kinase A isozyme switching. Ann NY Acad Sci 2005; 1058: 76-86.
67. Vincent-Dejean C, Cazabat L, Groussin L et al. Identification of a clinically homogenous subgroup of benign cortisol-secreting adrenocortical tumors characterized by alterations of the protein kinase A (PKA) subunits and high PKA activity. Eur J Endocrinol 2008; 158
68. Amieux PS, Cummings DE, Motamed K et al. Compensatory regulation of RIalpha protein levels in protein kinase A mutant mice. J Biol Chem 1997; 272: 3993-3998.
69. Kirschner LS, Kusewitt DF, Matyakhina L et al. A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res 2005; 65: 4506-4514.
70. Pavel E, Nadella K, Towns II WH et al. Mutation of Prkar1a causes osteoblast neoplasia driven by dysregulation of protein kinase A. Mol Endocrinol 2008; 22: 430-440.
71. Yin Z, Williams-Simons L, Parlow AF et al. Pituitary-specific knockout of the Carney complex gene Prkar1a leads to pituitary tumorigenesis. Mol Endocrinol 2008; 22: 380-387.
72. Yin Z, Jones GN, Towns II WH et al. Heart-specific ablation of Prkar1a causes failure of heart development and myxomagenesis. Circulation 2008; 117: 1414-1422.
73. Marfella-Scivittaro C, Quinones A, Orellana SA. cAMP-dependent protein kinase and proliferation differ in normal and polycystic kidney epithelia. Am J Physiol Cell Physiol 2002; 282: C693-C707.
74. Sands WA, Palmer TM. Regulating gene transcription in response to cyclic AMP elevation. Cell Signal 2008; 20: 460-466.
75. Zambon AC, Zhang L, Minovitsky S et al. Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A. Proc Natl Acad Sci USA 2005; 102: 8561-8566.
76. Deng C, Wang D, Bugaj-Gaweda B et al. Assays for cyclic nucleotide-specific phosphodiesterases (PDEs) in the central nervous system (PDE1, PDE2, PDE4, and PDE10). Curr Protoc Neurosci 2007; Chapter 7 (Suppl. 38): Unit 7.21.